Last reviewed 2026-04-23 · How we verify

R-MP and Procarbazine maintenance

University Hospital Freiburg · Phase 3 active Small molecule

R-MP and Procarbazine maintenance is a Alkylating agent Small molecule drug developed by University Hospital Freiburg. It is currently in Phase 3 development for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.

R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair.

R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair. Used for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.

At a glance

Generic name	R-MP and Procarbazine maintenance
Sponsor	University Hospital Freiburg
Drug class	Alkylating agent
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

R-MP is a chemotherapy medication that interferes with DNA replication and transcription, causing DNA damage and inhibiting cancer cell growth. Procarbazine is a chemotherapy medication that works by inhibiting DNA repair mechanisms, making cancer cells more susceptible to DNA damage. Together, they create a synergistic effect that enhances their individual anticancer activities.

Approved indications

Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma

Common side effects

Nausea
Vomiting
Fatigue
Hair loss
Anemia

Key clinical trials

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R-MP and Procarbazine maintenance CI brief — competitive landscape report
R-MP and Procarbazine maintenance updates RSS · CI watch RSS
University Hospital Freiburg portfolio CI

Frequently asked questions about R-MP and Procarbazine maintenance

What is R-MP and Procarbazine maintenance?

R-MP and Procarbazine maintenance is a Alkylating agent drug developed by University Hospital Freiburg, indicated for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.

How does R-MP and Procarbazine maintenance work?

R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair.

What is R-MP and Procarbazine maintenance used for?

R-MP and Procarbazine maintenance is indicated for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma.

Who makes R-MP and Procarbazine maintenance?

R-MP and Procarbazine maintenance is developed by University Hospital Freiburg (see full University Hospital Freiburg pipeline at /company/university-hospital-freiburg).

What drug class is R-MP and Procarbazine maintenance in?

R-MP and Procarbazine maintenance belongs to the Alkylating agent class. See all Alkylating agent drugs at /class/alkylating-agent.

What development phase is R-MP and Procarbazine maintenance in?

R-MP and Procarbazine maintenance is in Phase 3.

What are the side effects of R-MP and Procarbazine maintenance?

Common side effects of R-MP and Procarbazine maintenance include Nausea, Vomiting, Fatigue, Hair loss, Anemia.

Drug class: All Alkylating agent drugs
Manufacturer: University Hospital Freiburg — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Maintenance therapy in patients with anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma
Compare: R-MP and Procarbazine maintenance vs similar drugs
Pricing: R-MP and Procarbazine maintenance cost, discount & access